Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 283-290

  Shahin, Yousef ^a   Barnes, Rachel ^a   Barakat, Hashem ^a   Chetter, Ian C ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Ankle brachial pressure index; Intermittent claudication; Peripheral arterial disease; Walking distance

Indexed keywords

CAPTOPRIL; CILAZAPRIL; PERINDOPRIL; PLACEBO; RAMIPRIL;

ANKLE BRACHIAL INDEX; BLOOD PRESSURE; COHORT ANALYSIS; COUGHING; DATA EXTRACTION; DIZZINESS; DRUG WITHDRAWAL; EMBASE; FOLLOW UP; HUMAN; INTERMITTENT CLAUDICATION; MAXIMUM WALKING DISTANCE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PAIN FREE WALKING DISTANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; TREATMENT DURATION;

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; ANKLE BRACHIAL PRESSURE INDEX; INTERMITTENT CLAUDICATION; PERIPHERAL ARTERIAL DISEASE; WALKING DISTANCE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANKLE; ANKLE BRACHIAL INDEX; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WALKING;

EID: 84888084804     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.037     Document Type: Review

References (42)

1. Leng G.C., Lee A.J., Fowkes F.G., et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996, 25:1172-1181.
2. Newman A.B. Peripheral arterial disease: insights from population studies of older adults. JAm Geriatr Soc 2000, 48:1157e62.
3. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G. Inter-society consensus for the management of peripheral arterial disease (tasc ii). JVasc Surg 2007, 45(Suppl.S):S5-S67.
4. Clement D.L., Boccalon H., Dormandy J., Durand-Zaleski I., Fowkes G., Brown T. Aclinical approach to the management of the patient with coronary (co) and/or carotid (ca) artery disease who presents with leg ischaemia (lis). Int Angiol 2000, 19:97-125.
5. Gibbons G.H. Mechanisms of vascular remodeling in hypertension: role of autocrine-paracrine vasoactive factors. Curr Opin Nephrol Hypertens 1995, 4:189-196.
6. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295:180-189.
7. Antman E.M., Anbe D.T., Armstrong P.W., et al. Acc/aha guidelines for the management of patients with st-elevation myocardial infarction: a report of the american college of cardiology/american heart association task force on practice guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004, 110. e82-292.
8. National Institute for Health and Clinical Excellence Lower limb peripheral arterial disease: diagnosis and management 2012, (clinical guideline 147.), [accessed 02.07.13]. http://guidance.nice.org.uk/CG147.
9. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. NEngl J Med 2000, 342:145-153.
10. Ostergren J., Sleight P., Dagenais G., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004, 25:17-24.
11. Shahin Y., Mazari F., Chetter I. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg 2011, 9:209-213.
12. Elbourne D.R., Altman D.G., Higgins J.P., Curtin F., Worthington H.V., Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002, 31:140-149.
13. Cochrane handbook for systematic reviews of interventions version 5.0.2 2008, [updated September 2009], The Cochrane Collaboration, Available from:. http://www.cochrane-handbook.org, J.P. Higgins, S. Green (Eds.).
14. Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. JClin Epidemiol 1992, 45:769-773.
15. Review manager (RevMan) [Computer program] 2008, Version 5.0, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
16. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomised controlled trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
17. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
18. Roberts D.H., Tsao Y., Mcloughlin G.A., Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetolol and pindolol in hypertension complicated by intermittent claudication. Lancet 1987, 2(8560):650-653.
19. Spence J.D., Arnold J.M.O., Munoz C.E., et al. Angiotensin-converting enzyme inhibition with cilazapril does not improve blood flow, walking time, or plasma lipids in patients with intermittent claudication. JVasc Med Biol 1993, 4(1):23-28.
20. Overlack A., Adamczak M., Bachmann W., et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Theraputic Safety Collaborative Research Group. Am J Med 1994, 97(2):126-134.
21. Ahimastos A.A., Lawler A., Reid C.M., Blombery P.A., Kingwell B.A. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006, 144(9):660-664.
22. Ahimastos A.A., Walker P.J., Askew C., et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013, 309:453-460.
23. Shahin Y., Cockcroft J.R., Chetter I.C. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br J Surg 2013, 100:1154-1163.
24. Sonecha T.N., Nicolaides A.N., Kyprianou P., et al. The effect of enalapril on leg muscle blood flow in patients with claudication. Int Angiol 1990, 9:22-24.
25. Bernardi D., Bartoli P., Ferreri A., Geri A.B., Ieri A. Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using doppler ultrasound. Angiology 1988, 39:942-952.
26. Fabre J.E., Rivard A., Magner M., Silver M., Isner J.M. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis invivo. Circulation 1999, 99:3043-3049.
27. Li P., Kondo T., Numaguchi Y., et al. Role of bradykinin, nitric oxide, and angiotensin ii type 2 receptor in imidapril-induced angiogenesis. Hypertension 2008, 51:252-258.
28. Gokce N., Keaney J.F., Hunter L.M., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. JAm Coll Cardiol 2003, 41:1769-1775.
29. Drexler H. Factors involved in the maintenance of endothelial function. Am J Cardiol 1998, 82:3S-4S.
30. Payvandi L., Dyer A., McPherson D., et al. Physical activity during daily life and brachial artery flow-mediated dilation in peripheral arterial disease. Vasc Med 2009, 14:193-201.
31. Gordon M.B., Jain R., Beckman J.A., Creager M.A. The contribution of nitric oxide to exercise hyperemia in the human forearm. Vasc Med 2002, 7:163-168.
32. Meredith I.T., Currie K.E., Anderson T.J., Roddy M.A., Ganz P., Creager M.A. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol 1996, 270:H1435-H1440.
33. Shahin Y., Khan J.A., Samuel N., Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011, 216:7-16.
34. Safar M.E., Levy B.I., Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003, 107:2864-2869.
35. London G.M., Marchais S.J., Guerin A.P., Pannier B. Arterial stiffness: pathophysiology and clinical impact. Clin Exp Hypertens 2004, 26:689-699.
36. Ahimastos A.A., Dart A.M., Lawler A., Blombery P.A., Kingwell B.A. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. JHypertens 2008, 26:1037-1042.
37. Shahin Y., Khan J.A., Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 2012, 221:18-33.
38. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin i-converting enzyme gene accounting for half the variance of serum enzyme levels. JClin Invest 1990, 86:1343-1346.
39. Brewster L.M., van Montfrans G.A., Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004, 141:614-627.
40. Beebe H.G., Dawson D.L., Cutler B.S., et al. Anew pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999, 159:2041-2050.
41. Dawson D.L., Cutler B.S., Hiatt W.R., et al. Acomparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000, 109:523-530.
42. Gardner A.W., Poehlman E.T. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995, 274:975-980.